Targets › SERPINA1
8 programs from 8 companies in 10 trials: 5 Phase 1, 4 Phase 3, 1 Phase 2; Metabolic and endocrine, Infectious disease, Respiratory; next expected readout Dec 2026.
Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. (UniProt, P01009)
Open in Phaseline: the race on SERPINA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Grifols Therapeutics | Alpha-1 15% (DRUG): Alpha1-Proteinase Inhibitor Subcutaneous (Human), 15% Protease inhibitor replacement therapy - recombinant alpha-1 antitrypsin (AAT) replacement | SERPINA1 | Phase 3 | Alpha 1 Antitrypsin Deficiency | Sep 2027 |
| Takeda | Fazirsiran Z-AAT reducing agent; inhibits expression of Z-AAT protein | SERPINA1 | Phase 3 | Alpha1-Antitrypsin Deficiency | Aug 2028 |
| Medical University Innsbruck | Alfa1 Antitrypsin Serine protease inhibitor; suppresses neutrophil elastase and reduces inflammation | SERPINA1 | Phase 2 | Alcohol-Associated Hepatitis | Dec 2026 |
| Krystal Biotech | KB408 Replication-defective HSV-1 vector expressing full-length human SERPINA1 | SERPINA1 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Dec 2026 |
| Wave Life Sciences USA | WVE-006 RNA editing oligonucleotide to correct alpha-1 antitrypsin deficiency | SERPINA1 | Phase 1 | Alpha-1 Antitrypsin Deficiency | Sep 2027 |
| Weill Medical College of Cornell University | AAV8hAAT(AVL) AAV8-delivered alpha-1 antitrypsin (oxidation-resistant variant) gene therapy | SERPINA1 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Apr 2028 |
| Beam Therapeutics | BEAM-302 lipid nanoparticle (LNP)-based alpha-1 antitrypsin (AAT) gene therapy | SERPINA1 | Phase 1 | Alpha 1-Antitrypsin Deficiency | May 2028 |
| Tessera Therapeutics | TSRA-196 In-vivo genome editing via lipid nanoparticles to increase alpha-1 antitrypsin expression | SERPINA1 | Phase 1 | Alpha-1 Antitrypsin Deficiency (AATD) | Mar 2029 |
Alpha 1-Antitrypsin Deficiency (3) Alpha1-Antitrypsin Deficiency (3) Alpha-1 Antitrypsin Deficiency (AATD) (1) Alpha-1 Antitrypsin Deficiency (1) Alcohol-Associated Hepatitis (1) Alpha 1 Antitrypsin Deficiency (1)
small molecule (6), other (2)
Krystal Biotech (1) Takeda (1) Weill Medical College of Cornell University (1) Tessera Therapeutics (1) Wave Life Sciences USA (1) Beam Therapeutics (1) Medical University Innsbruck (1) Grifols Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.